Health Canada Clears Palisade Bio's Phase 2b UC Trial, Expanding Global Reach
PALI has more than doubled off its 52-week low of $0.58.
Summary
Palisade Bio received Health Canada CTA clearance for ASCENTRA-UC, its Phase 2b trial of oral PALI-2108 in ulcerative colitis. This expands the trial's global footprint beyond the U.S., where FDA IND clearance was already secured. The trial will enroll approximately 204 patients with moderately to severely active UC, with primary 12-week induction results expected in H2 2027. The once-daily oral dosing at 15/30 mg positions PALI-2108 as a potential competitor in the UC space if efficacy and safety hold. This follows the FDA's IND clearance for PALI-2108 in Crohn's disease announced yesterday, underscoring the company's momentum in advancing its pipeline. The long timeline to data readout may temper near-term enthusiasm, but the regulatory green light de-risks trial execution and supports enrollment.
At the time of this announcement, PALI was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $294.5M. The 52-week trading range was $0.58 to $2.86. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.